BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Feingold PL, Surman DR, Brown K, Xu Y, McDuffie LA, Shukla V, Reardon ES, Crooks DR, Trepel JB, Lee S, Lee MJ, Gao S, Xi S, McLoughlin KC, Diggs LP, Beer DG, Nancarrow DJ, Neckers LM, Davis JL, Hoang CD, Hernandez JM, Schrump DS, Ripley RT. Induction of Thioredoxin-Interacting Protein by a Histone Deacetylase Inhibitor, Entinostat, Is Associated with DNA Damage and Apoptosis in Esophageal Adenocarcinoma. Mol Cancer Ther 2018;17:2013-23. [PMID: 29934340 DOI: 10.1158/1535-7163.MCT-17-1240] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Liao L, Yao Z, Fang W, He Q, Xu WW, Li B. Epigenetics in Esophageal Cancer: From Mechanisms to Therapeutics. Small Methods 2020;4:2000391. [DOI: 10.1002/smtd.202000391] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Li YH, Tong KL, Lu JL, Lin JB, Li ZY, Sang Y, Ghodbane A, Gao XJ, Tam MS, Hu CD, Zhang HT, Zha ZG. PRMT5-TRIM21 interaction regulates the senescence of osteosarcoma cells by targeting the TXNIP/p21 axis. Aging (Albany NY) 2020;12:2507-29. [PMID: 32023548 DOI: 10.18632/aging.102760] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
3 Pickering OJ, Breininger SP, Underwood TJ, Walters ZS. Histone Modifying Enzymes as Targets for Therapeutic Intervention in Oesophageal Adenocarcinoma. Cancers (Basel) 2021;13:4084. [PMID: 34439236 DOI: 10.3390/cancers13164084] [Reference Citation Analysis]
4 Surman DR, Xu Y, Lee MJ, Trepel J, Brown K, Ramineni M, Splawn TG, Diggs LP, Hodges HC, Davis JL, Lee HS, Burt BM, Ripley RT. Therapeutic Synergy in Esophageal Cancer and Mesothelioma Is Predicted by Dynamic BH3 Profiling. Mol Cancer Ther 2021;20:1469-80. [PMID: 34088830 DOI: 10.1158/1535-7163.MCT-20-0887] [Reference Citation Analysis]
5 Huang G, Pan ST. ROS-Mediated Therapeutic Strategy in Chemo-/Radiotherapy of Head and Neck Cancer. Oxid Med Cell Longev 2020;2020:5047987. [PMID: 32774675 DOI: 10.1155/2020/5047987] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
6 Zhang B, Lyu J, Yang EJ, Liu Y, Wu C, Pardeshi L, Tan K, Chen Q, Xu X, Deng CX, Shim JS. Class I histone deacetylase inhibition is synthetic lethal with BRCA1 deficiency in breast cancer cells. Acta Pharm Sin B 2020;10:615-27. [PMID: 32322466 DOI: 10.1016/j.apsb.2019.08.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
7 Quagliano A, Gopalakrishnapillai A, Barwe SP. Understanding the Mechanisms by Which Epigenetic Modifiers Avert Therapy Resistance in Cancer. Front Oncol 2020;10:992. [PMID: 32670880 DOI: 10.3389/fonc.2020.00992] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
8 Chen Y, Ning J, Cao W, Wang S, Du T, Jiang J, Feng X, Zhang B. Research Progress of TXNIP as a Tumor Suppressor Gene Participating in the Metabolic Reprogramming and Oxidative Stress of Cancer Cells in Various Cancers. Front Oncol 2020;10:568574. [PMID: 33194655 DOI: 10.3389/fonc.2020.568574] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
9 Bridgeman S, Ellison G, Newsholme P, Mamotte C. The HDAC Inhibitor Butyrate Impairs β Cell Function and Activates the Disallowed Gene Hexokinase I. Int J Mol Sci 2021;22:13330. [PMID: 34948127 DOI: 10.3390/ijms222413330] [Reference Citation Analysis]
10 Gao Y, Qi JC, Li X, Sun JP, Ji H, Li QH. Decreased expression of TXNIP predicts poor prognosis in patients with clear cell renal cell carcinoma. Oncol Lett 2020;19:763-70. [PMID: 31897192 DOI: 10.3892/ol.2019.11165] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
11 Friedrich A, Assmann AS, Schumacher L, Stuijvenberg JV, Kassack MU, Schulz WA, Roos WP, Hansen FK, Pflieger M, Kurz T, Fritz G. In Vitro Assessment of the Genotoxic Hazard of Novel Hydroxamic Acid- and Benzamide-Type Histone Deacetylase Inhibitors (HDACi). Int J Mol Sci 2020;21:E4747. [PMID: 32635356 DOI: 10.3390/ijms21134747] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]